Plain-English translation of NCT06333314 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing , an immunotherapy medication, as a first-line treatment for patients with advanced cancers that have a specific genetic feature called dMMR or MSI. Half of participants will receive by IV infusion on a set schedule, while the other half will receive standard . If the group's cancer progresses, they may switch to receive as well.
Many advanced cancers with these genetic changes don't respond well to standard alone. This trial is designed to see whether this medication, which helps the immune system fight cancer, might work better as a first treatment option for these patients.
You likely qualify if…
You likely don't qualify if…
After initial screening and confirmation that your cancer has the right genetic marker, you will be randomly assigned to either receive by IV infusion (starting with 500mg every 3 weeks for 4 doses, then 1000mg every 6 weeks) or standard . You will have regular clinic visits for treatment and monitoring. The study lasts up to 24 months, with tumor evaluations every few weeks to see how you are responding. If you are in the group and your cancer progresses, you may have the option to switch to treatment.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
France